Targeting death receptors to fight cancer: from biological rational to clinical implementation.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current Medicinal Chemistry

• Publication date

  2010-08-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/092986710791859342PMID 20586721
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation

  2010cited by this paper
• Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

  2010cited by this paper
• Death receptors: targets for cancer therapy.

  2010cited by this paper
• Apoptosis and cancer: the genesis of a research field

  2009cited by this paper
• Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib

  2009cited by this paper
• TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges.

  2009cited by this paper
• Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

  2009cited by this paper
• TRAIL as a target in anti-cancer therapy.

  2009cited by this paper
• Improving TNF as a cancer therapeutic: Tailor‐made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects

  2009cited by this paper
• TNF-based isolated hepatic perfusion.

  2009cited by this paper
• Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands.

  2009cited by this paper
• The many roles of FAS receptor signaling in the immune system.

  2009cited by this paper
• TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

  2009cited by this paper
• The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells.

  2009cited by this paper
• Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.

  2009cited by this paper
• Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.

  2009cited by this paper
• Tumour necrosis factor and cancer

  2009cited by this paper
• Targeting the Apoptosome for Cancer Therapy

  2009cited by this paper
• Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression

  2009cited by this paper
• Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.

  2008cited by this paper
• Death receptors as targets for anti-cancer therapy

  2008cited by this paper
• Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein.

  2008cited by this paper
• Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein

  2008cited by this paper
• CD95 Stimulation Results in the Formation of a Novel Death Effector Domain Protein-containing Complex*

  2008cited by this paper
• Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.

  2008cited by this paper
• Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors.

  2008cited by this paper
• Tumor necrosis factor‐mediated interactions between inflammatory response and tumor vascular bed

  2008cited by this paper
• TRAIL death receptors as tumor suppressors and drug targets

  2008cited by this paper
• Mcl-1: a gateway to TRAIL sensitization.

  2008cited by this paper
• Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis

  2008cited by this paper
• Targeting the extrinsic apoptosis pathway in cancer.

  2008cited by this paper
• A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma

  2008cited by this paper
• Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials

  2008cited by this paper
• Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

  2008cited by this paper
• Modulation of TRAIL-induced apoptosis by HDAC inhibitors.

  2008cited by this paper
• Trail receptors: targets for cancer therapy.

  2008cited by this paper
• Directing cancer cells to self-destruct with pro-apoptotic receptor agonists

  2008cited by this paper
• Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

  2008cited by this paper
• A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.

  2007cited by this paper
• Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma

  2007cited by this paper
• Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

  2007cited by this paper
• Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects

  2007cited by this paper
• TRAIL: a multifunctional cytokine.

  2007cited by this paper
• Barriers to effective TRAIL-targeted therapy of malignancy.

  2007cited by this paper
• Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL.

  2007cited by this paper
• The Apoptosome: Emerging Insights and New Potential Targets for Drug Design

  2007cited by this paper
• The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.

  2007cited by this paper
• Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

  2007cited by this paper
• DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells

  2007cited by this paper
• Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response

  2007cited by this paper
• Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.

  2007cited by this paper
• Targeting death-inducing receptors in cancer therapy

  2007cited by this paper
• Different modulation of TRAIL‐induced apoptosis by inhibition of pro‐survival pathways in TRAIL‐sensitive and TRAIL‐resistant colon cancer cells

  2006cited by this paper
• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

  2006cited by this paper
• Chemotherapeutic approaches for targeting cell death pathways.

  2006cited by this paper
• Eliminating Established Tumor in nu/nu Nude Mice by a Tumor Necrosis Factor-α-Related Apoptosis-Inducing Ligand–Armed Oncolytic Adenovirus

  2006cited by this paper
• Following the TRAIL to apoptosis

  2006cited by this paper
• Mcl-1 Interacts with Truncated Bid and Inhibits Its Induction of Cytochrome c Release and Its Role in Receptor-mediated Apoptosis*

  2006cited by this paper
• Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.

  2006cited by this paper
• TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.

  2006cited by this paper
• Death receptor signaling

  2005cited by this paper
• Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor

  2005cited by this paper
• Tumor necrosis factor, cancer and anticancer therapy.

  2005cited by this paper
• Targeting the Fas/Fas ligand pathway in cancer

  2005cited by this paper
• Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis

  2005cited by this paper
• The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games

  2005cited by this paper
• Enhancing TRAIL-induced apoptosis by Bcl-XL siRNA

  2005cited by this paper
• TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor α, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up

  2005cited by this paper
• The Proteasome Inhibitor Bortezomib (Velcade) Sensitizes Some Human Tumor Cells to Apo2L/TRAIL‐Mediated Apoptosis

  2005cited by this paper
• Targeting Apoptosis Pathways in Cancer Therapy

  2005cited by this paper
• Considering Fas ligand as a target for therapy

  2005cited by this paper
• The Fas signalling pathway and its role in the pathogenesis of cancer.

  2004cited by this paper
• A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities

  2004cited by this paper
• Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells

  2004cited by this paper
• Sensitization to the Lysosomal Cell Death Pathway upon Immortalization and Transformation

  2004cited by this paper
• Induction of Endothelial Nitric Oxide Synthase Expression by Melanoma Sensitizes Endothelial Cells to Tumor Necrosis Factor-Driven Cytotoxicity

  2004cited by this paper
• Tumor necrosis factor: an apoptosis JuNKie?

  2004cited by this paper
• p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site

  2004cited by this paper
• Tissue Distribution of the Death Ligand TRAIL and Its Receptors

  2004cited by this paper
• Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications.

  2004cited by this paper
• TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.

  2004cited by this paper
• Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity.

  2004cited by this paper
• TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model

  2004cited by this paper
• Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer.

  2004cited by this paper
• Interdimer processing mechanism of procaspase‐8 activation

  2003cited by this paper
• Biological functions of tumor necrosis factor cytokines and their receptors.

  2003cited by this paper
• Live and let die: regulatory mechanisms in Fas-mediated apoptosis.

  2003cited by this paper
• The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

  2003cited by this paper
• Current uses of isolated limb perfusion in the clinic and a model system for new strategies.

  2003cited by this paper
• Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion

  2003cited by this paper
• The CD95 type I/type II model.

  2003cited by this paper
• The Bcl-2-regulated apoptotic pathway

  2003cited by this paper
• Generation of a FasL-based Proapoptotic Fusion Protein Devoid of Systemic Toxicity due to Cell-surface Antigen-restricted Activation*

  2003cited by this paper
• Signalling pathways of the TNF superfamily: a double-edged sword

  2003cited by this paper
• All in the family: evolutionary and functional relationships among death receptors

  2003cited by this paper
• Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.

  2003cited by this paper
• TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: state of the art and future trends.

  2003cited by this paper
• Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1

  2002cited by this paper
• Ceramide and cell death receptor clustering.

  2002cited by this paper
• Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy.

  2002cited by this paper

• EX527, a sirtuins 1 inhibitor, sensitizes T-cell leukemia to death receptor-mediated apoptosis by downregulating cellular FLICE inhibitory protein

  2024cites this paper
• Reversine induces cell cycle arrest and apoptosis via upregulation of the Fas and DR5 signaling pathways in human colorectal cancer cells.

  2019cites this paper
• Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.

  2018cites this paper
• Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells

  2016cites this paper
• Fas/FasL Pathway Participates in Regulation of Antiviral and Inflammatory Response during Mousepox Infection of Lungs

  2015cites this paper
• Genetic Variants in the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Death Receptor Genes Contribute to Susceptibility to Bladder Cancer

  2015cites this paper
• Role of Fas/FasL signaling in regulation of anti-viral response during HSV-2 vaginal infection in mice.

  2014cites this paper
• Cytotoxicity of (-)-vitisin B in human leukemia cells

  2013cites this paper
• HSV-2 Regulates Monocyte Inflammatory Response via the Fas/FasL Pathway

  2013cites this paper
• Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis

  2013cites this paper
• Antcin B and its ester derivative from Antrodia camphorata induce apoptosis in hepatocellular carcinoma cells involves enhancing oxidative stress coincident with activation of intrinsic and extrinsic apoptotic pathway.

  2011cites this paper
• Targeting Fas in osteoresorptive disorders

  2010cites this paper